Single-centre Open Label Exploratory Phase IIb Pilot Study of Exogenous Oral Melatonin for the Treatment of Nocturia in Adults With Parkinson's Disease

Trial Profile

Single-centre Open Label Exploratory Phase IIb Pilot Study of Exogenous Oral Melatonin for the Treatment of Nocturia in Adults With Parkinson's Disease

Recruiting
Phase of Trial: Phase II

Latest Information Update: 28 Feb 2017

At a glance

  • Drugs Melatonin (Primary)
  • Indications Nocturia
  • Focus Therapeutic Use
  • Most Recent Events

    • 17 Mar 2016 Status changed from not yet recruiting to recruiting as reported by United Kingdom Clinical Research Network record.
    • 17 Feb 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top